Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

tacrine (Discontinued)Brand and Other Names:Cognex

 
 
 

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

capsule

  • 10mg
  • 20mg
  • 30mg
  • 40mg
more...

Alzheimer's Dementia

10-20 mg PO QID; no more than 160 mg/day

Monitor LFTs every other week from weeks 4-16, then q3Months

Take between meals, unless GI upset

Hepatic Impairment

LFTs >3-5x upper limit of normal, reduce dose to 10mg PO QID, monitor LFT's qWeek, resume dose titration and qoWeek monitoring when ALT return to normal

LFT's >5x upper limit of normal, stop treatment monitor for symptom hepatitis, follow ALT until WNL's and rechallenge with initial dose 10 mg PO QID, monitor LFT's qweek, if after 6 weeks ALT wnl's may retry dose titration schedule, continue qweek ALT monitoring for 16 weeks then qmonths for 2 months then q3Months thereafter

<18 years old: Safety & efficacy not established

Next

Interactions

Interaction Checker

tacrine and

No Results

     
     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            Sort by :  
             activity indicator 
            Previous
            Next

            Adverse Effects

            >10%

            Incr LFT's (26-30%)

            Nausea/vomiting (26-30%)

            Diarrhea (15-20%)

            Headache (11-15%)

            Dizziness (11-15%)

            1-10%

            Dyspepsia (6-10%)

            Anorexia (6-10%)

            Abdominal pain (6-10%)

            Myalgia (6-10%)

            Confusion (6-10%)

            Ataxia (6-10%)

            Insomnia (6-10%)

            Rhinitis (6-10%)

            Rash (6-10%)

            Fatigue (1-5%)

            Weight loss (1-5%)

            Constipation (1-5%)

            Somnolence (1-5%)

            Tremor (1-5%)

            Anxiety (1-5%)

            Previous
            Next

            Warnings

            Contraindications

            Hypersensitivity

            Drug-induced bilirubin >3 mg/dL [51.3 umol/L]

            Previous
            Next

            Pregnancy & Lactation

            Pregnancy Category: C

            Lactation: unknown

            Pregnancy Categories

            A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA:Information not available.

            more...
            Previous
            Next

            Pharmacology

            Half-Life: 2-4 hr

            Peak Plasma Time: 1-2 hr

            Bioavailability: 17%

            Protein Bound: 55%

            Vd: 349 L

            Metabolism: hepatic P450 enzyme CYP1A2

            Enzymes inhibited: CYP1A2

            Mechanism of Action

            Centrally acting cholinesterase inhibitor

            Previous
            Next

            Images

            Previous
            Next
             
             
             
            All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.